北欧炎症肠病治疗策略试验:NORDTREAT随机对照生物标志物策略试验的协议
Martin Rejler1,2,3, Johannes David Füchtbauer4,5,6, Lóa G Davíðsdóttir7
1School of Health and Medical Sciences, Örebro University, Örebro, Sweden.
BMJ open
|August 1, 2024
概括
这项研究测试了一种新的蛋白质特征,以个性化炎症性肠病 (IBD) 治疗. 早期识别高风险患者可以改善结果,避免IBD疗法的不必要毒性.
科学领域:
- 胃肠病学 胃肠病学
- 临床试验 临床试验
- 生物标志物发现发现
背景情况:
- 由于缺乏可靠的预后标志物,有效的炎症性肠病 (IBD) 管理受到挑战.
- 目前的治疗策略 (逐步向上与自上而下) 存在治疗不足或过度治疗的风险.
- 需要个性化医疗方法来优化IBD患者的护理.
研究的目的:
- 为了评估IBD个性化治疗的可行性,使用预后血清蛋白签名.
- 在诊断时根据预测的疾病进程对IBD患者进行分层.
- 为了比较生物标记指导和传统管理策略之间的治疗结果.
主要方法:
- 一个多中心,生物标志物策略,开放标签受控试验 (NORDTREAT).
- 随机选择 (1:1) 符合条件的患者接受治疗,或没有访问蛋白质签名.
- 高风险患者的自上而下的治疗 (蛋白质签名阳性) 与其他患者的逐步常规管理.
- 主要终点:52周内无皮质类固醇的临床和内镜缓解的组合.
主要成果:
- 在四个北欧国家正在招聘.
- 该试验评估了蛋白质样本表明潜在严重疾病轨迹的患者的结果.
- 由于IBD的外科干预被定义为治疗失败.
结论:
- 该NORDTREAT试验旨在建立一个基于生物标志物的战略,用于个性化IBD管理.
- 成功实施可能会导致量身定制的疗法,改善患者的治疗结果.
- 结果将通过同行评审的出版物和会议演讲传播.
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
Inflammatory Bowel Disease IV: Pharmacological Management
124
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
124
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
149
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
149
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
124
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
124
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
110
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
110
Drugs for Treatment of Ulcerative Colitis in IBD
133
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
133


